II. Indications
III. Mechanism
- See ACE Inhibitor
- Carboxyl-containing Angiotensin-converting enzyme (ACE) inhibitor
- Benazapril is a prodrug, converted to its active form benazeprilat in the liver
IV. Dosing: Adults
- Adequate 24 hour control may require divided dosing twice daily
-
Hypertension
- Start 10 mg orally daily
- Start at 5 mg orally daily in elderly, Diuretic use, GFR <30
- Start at 5 mg in Congestive Heart Failure (CHF)
- Target 20-40 mg/day
- Start 10 mg orally daily
- Maximum: 80 mg/day (40 mg/day in CHF)
-
Renal Dosing
- GFR <30 ml/min: Start at 5 mg
V. Dosing: Children (age >=6 years old)
- Contraindicated if GFR <30 ml/min or age <6 years old
-
Hypertension
- Start 0.2 mg/kg/day up to 10 mg/day
- Maximum: 0.6 mg/day up to 40 mg/day
VI. Supplied
- Available as unscored generic tablets: 5, 10, 20 and 40 mg
VII. Metabolism
- Primarily renal excretion (as benzeprilat)
VIII. Adverse Effects
- See ACE Inhibitor
IX. Safety
- See ACE Inhibitor
- Pregnancy Category X
- Avoid in Lactation
X. Resources
XI. References
- (2016) Presc Lett, Resource #321151, ACE Inhibitor Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 68-9
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
| Definition (NCI) | A carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, benazepril is metabolized to its active form benazeprilat. Benazeprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II resulting in vasodilation. Benazeprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C044946 |
| SnomedCT | 108572003, 372511001 |
| LNC | LP171387-6 |
| English | 1H-1-Benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,R*))-, benazepril, benzazepril, benazapril, benazepril (medication), benazepril [Chemical/Ingredient], BENAZEPRIL, Benazepril (product), Benazepril (substance), Benazepril |
| Spanish | benacepril (producto), benazepril (producto), benacepril, benacepril (sustancia), benaceprilo, benazepril (sustancia), benazepril |
Ontology: Lotensin (C0721436)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C044946 |
| English | Lotensin, lotensin, Cibacen, Cibacène, Novartis brand of benazepril hydrochloride |
